These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27106017)

  • 1. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
    Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
    Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
    Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
    Chappell NP; Miller CR; Fielden AD; Barnett JC
    J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Case AS; Rocconi RP; Partridge EE; Straughn JM
    Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
    Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
    Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
    Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
    Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Havrilesky LJ; Secord AA; Kulasingam S; Myers E
    Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Lairson DR; Parikh RC; Cormier JN; Du XL
    Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
    Fisher M; Gore M
    Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL; Meisner BC; Frick KD; Armstrong DK
    Cancer; 2007 Apr; 109(8):1513-22. PubMed ID: 17354232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
    Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
    Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.